| Předmět: |
|
| Zdroj: |
Health & Medicine Week; 2/16/2024, p1256-1256, 1p |
| Abstrakt: |
A new report from the Dana-Farber Cancer Institute in Boston, Massachusetts discusses the potential therapeutic targeting of the BCL-2-associated X protein (BAX) in diseases involving abnormal cell survival or death. The researchers identified a compound called covalent BAX inhibitor 1 (CBI1) that interacts with BAX and inhibits its activation. This discovery provides insights into a pharmacologic strategy for suppressing unwanted cell death in various diseases. The research has been peer-reviewed and published in Nature Chemical Biology. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
